H.C. Wainwright downgraded Tempest Therapeutics (TPST) to Neutral from Buy without a price target after the company announced it is seeking to explore strategic alternatives to advance its pipeline of clinical stage oncology assets. The firm says a “dire” funding environment and recent shakeups at the FDA “bring about plenty of regulatory uncertainty at this time.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TPST: